ID 1617 - Metylosulfonylometan (również z glukozaminą)

PL: Metylosulfonylometan (również z glukozaminą)
EN: Methylsulfonylmethane (MSM) in combination with glucosamine HCl
Pdf:

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claims is methylsulfonylmethane (MSM), either alone or in combination with glucosamine hydrochloride.
MSM is about one-third sulphur and a metabolite of dimethylsulfoxide (DMSO).
Glucosamine is an amino monosaccharide where a hydroxyl group (-OH) is replaced with an amino group (-NH2) (2-amino-2-deoxy-D-glucose). The raw material is derived from chitin, a biopolymer present in the exoskeleton of marine invertebrate animals (Foot and Mulholland, 2005). Glucosamine is usually formulated as the hydrochloride salt or as glucosamine sulphate.
The Panel considers that the food constituent, MSM, either alone or in combination with glucosamine hydrochloride, is sufficiently characterised.

2. Znaczenie oświadczenia dla zdrowia człowieka

The claimed effects are “joint health” and “joint support”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings, the Panel notes that these claimed effects relate to the maintenance of normal joints.
The Panel considers that maintenance of normal joints is beneficial to human health.

3. Naukowe uzasadnienia wpływu na zdrowie człowieka - Utrzymanie prawidłowego stanu stawów

Two systematic reviews and two double-blind, placebo-controlled trials have been provided for the substantiation of the claimed effect (Usha and Naidu, 2004; Kim et al., 2006; Ameye and Chee, 2006; Brien et al., 2008).
All the human studies presented on the effects of MSM, either alone or in combination with glucosamine hydrochloride, on joint health (e.g. joint pain, joint structure/function) have been conducted in patients with clinical diagnosis of (primarily knee) osteoarthritis (OA). OA is the most common joint disease worldwide (Issa and Sharma, 2006; Corti and Rigon, 2003; Arden and Nevitt, 2006) and a major cause of disability (Hunter et al., 2008; Pollard and Johnston, 2006; Sarzi-Puttini et al., 2005; Ethgen et al., 2004).
The Panel considers that the evidence provided does not establish that patients with OA are representative of the general population with regard to the status of joint tissues, or that results
obtained in studies on subjects with OA relating to the treatment of symptoms of this disease (e.g. erosion of articular cartilage, reduced mobility of joints) can be extrapolated to the maintenance of normal joints in the general population.
The Panel concludes that a cause and effect relationship has not been established between the consumption of MSM, either alone or in combination with glucosamine hydrochloride, and the maintenance of normal joints.

Warunki i możliwe ograniczenia stosowania oświadczenia

Glucosamine (1246.5mg/ day) + MSM (1500mg/day)